1 / 36

Centre for NanoHealth Future Healthcare

Centre for NanoHealth Future Healthcare. Dr Steve Conlan Director - Centre for NanoHealth Institute of Life Science School of Medicine. Overview. Nanotechnology NanoHealth Impact of NanoHealth Centre for NanoHealth Challenges and Opportunities R&D.

jerold
Download Presentation

Centre for NanoHealth Future Healthcare

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Centre for NanoHealthFuture Healthcare Dr Steve Conlan Director - Centre for NanoHealth Institute of Life Science School of Medicine

  2. Overview • Nanotechnology • NanoHealth • Impact of NanoHealth • Centre for NanoHealth • Challenges and Opportunities • R&D

  3. Please turn off your Nanotechnology based devices.

  4. The nano-scale

  5. What is NanoHealth?

  6. Nanotechnology… • Ability to manipulate and control the properties and interaction of material where at least 1-D is nm. • Structural • Mechanical • Electronic • Optical • Chemical • Biological • Computational • Modelling Multidisciplinary …For Healthcare

  7. The impact of NanoHealth

  8. NanoHealth… … has the potential to impact on the prevention, early and reliable diagnosis and treatment of diseases. • NanoHealth embraces five main sub-disciplines • that in many ways are overlapping • • Analytical Tools • • Imaging Tools • • Materials and Devices • • Novel Therapeutics and Drug Delivery Systems: ‘Nanomedicines’ • • Clinical, Regulatory and Toxicological Issues European Technology Platform on NanoMedicine Vision Paper (2005) ESF forward look on Nanomedicine (2005)

  9. Impact on Healthcare • Diagnosing and treating diseases • Enhancing early intervention • Non-hospital environments • Personalised Medicine

  10. Economic Impact

  11. Economic Impact

  12. Global Networks/Global Investment EU, US, South America and Asia Alliance for Nanohealth ETP for Nanomedicine

  13. Centre for NanoHealth

  14. Partnership for Success Multidisciplinary Nanotechnology Centre More than £5M funding in 2002 from HEFCW, Royal Society/ Wolfson Foundation, SRIF and Swansea University Home in Engineering, major research centre (20 academic staff, 20 RAs and 40 PhD students) Institute of Life Science £52m collaborative venture between IBM, Swansea University, WAG, opening its doors in 2007 Home in the Medical School, 25 specialist teams (27 Professors and 220 Research active staff) Outstanding RAE 2008 results (THES) MNC 5th out of 52 in UK in General Engineering, 80% of activity rated 4* and 3* ILS 7th out of 70 in UK in Allied and Professional Health, 55% of activity 4* and 3*

  15. Partnership for Success • Successfully managed HEFCW project • Model interdisciplinary centre • Self-sustaining (£2M per year) • Strong links with business/IP • Pan-Wales focus for nanotech • Successfully managed Objective 1 project • On time - On budget • Outputs met– sustainability/job creation/strong links with business/IP • Blue C IBM partnership • Interdisciplinary research base • University NHS Trust • Patient base of 600,000+ • Partnership with ILS and MNC • Joint MNC and ILS laboratories in Morriston Hospital • Commitment to CNH

  16. Uniqueinterdisciplinary R&D environment Based on theapplication of Nanotechnology Leadinginnovations in Healthcare. Driving the Knowledge Economy Centre for NanoHealth • £22M EU Convergence funded project, started January 2009 • 12 new staff (8 academic, 4 project management and delivery). • £13M investment in state of the art open access nano- and bio-facilities. • Industry to come and work with us, access to facilities, expertise and incubation space.

  17. Centre for NanoHealth

  18. Project Funding • £22 Million, 5 year Knowledge Economy project • Supported by: • WEFO [£10.5 Million] • DHSS [£1.5 Million] • Swansea University [£7.6 Million] • Industry [£2.5 Million]

  19. CNH Targets & Deliverables • Establishing a European R&D Centre of Excellence • Assisting 400 Enterprises (>80% Welsh SMEs) • Assisting 100 Individuals • Creating 450 Jobs • Achieving sustainability by 2014 • Through Welsh, UK, Industrial and EU funding

  20. CNH Building opens Q3 2011 Facilities available now • Nano-suite • Class 100/1000 ‘dirty’ clean room • Bio-clean room • Nanostructure growth • SEM & AFM/SNOM • NMR & Rheology • Printing and Coating • Bio-suite • NanoToxicology • Cell Imaging • Tissue Engineering • Molecular biology • Microbiology Direct access to: Clinical Trials Unit & Patient imaging (MRI&CT)

  21. Projects challenges & opportunities

  22. Challenges & Opportunities • Company recruitment • Business development • IP • State Aid • Managing stakeholder expectations • Sustainability

  23. Company recruitment & Business development • Project must offer real opportunities to businesses across Wales • Take the project to the companies • Launch Events/BioWales/KTNs etc • Initial assistance is only the first step in the relationship • Ensure multiple entries for engagement • Pool of relevant expertise is essential • Awareness of funding opportunities is essential • Beware of ERDF overload – internal/institutional management vital

  24. CNH • Access Clinical/Biomedical/Engineering teams • Fully integrated work flow • Access at any stage • Translational applications • Great opportunities in a new area of healthcare

  25. IP / IPR • IP policy of University has to be flexible • Case by case consideration – one model DOES NOT fit all • Primary consideration to companies – SHOW STOPPER • Has to be managed differently to IP generated in house • Early negotiation • Companies understand and appreciate position of University • State Aid compliance

  26. State Aid • Necessarily a major consideration under European law • Documentation from WEFO offers clarity in their expectations • Seek legal advice on wording used in business plans • De minimus scheme easy to implement

  27. Sustainability – R&D pipeline • Start early • Awareness of all opportunities • Development pipeline

  28. Delivery = Team work!! • Medicine • Engineering • Finance • Research and Innovation • Procurement • VC’s office • ABMUHB • External project managers / build team • WEFO Early/Continued/Agreed/Managed engagement

  29. CNH operational structure

  30. NanoHealth R&D

  31. Diagnostics – Biosensors Novel Materials Electrode Antigen Antibody Nanowire Ultra-sensitive biosensor for the detection of bio-markers using bio-compatible ZnO nanowires. ZnO nanowires (AFM)

  32. Cellular Analysis for Clinical Diagnostics • Surface topography. • Material properties. • Spatial resolution 5 - 20 nm.

  33. Volume additive printing for the integration of biosensors with flexible polymer electronics, photonics and displays. Biosensors / Biomarker Detection

  34. Centre for NanoHealth

  35. Centre for NanoHealth

More Related